Tremelimumab
This immune checkpoint inhibitor is a monoclonal antibody that blocks CTLA-4, a protein that acts as a brake on the immune system, and is used in combination with durvalumab to treat certain types of liver cancer (hepatocellular carcinoma) and unresectable non-small cell lung cancer. By releasing the immune system's brakes, it helps the body's own defenses attack cancer cells more effectively. Like all checkpoint inhibitors, it can cause serious immune-related side effects affecting any organ in the body.
Terapötik Alanlar
Etki Mekanizması
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
This immune checkpoint inhibitor is a monoclonal antibody that blocks CTLA-4, a protein that acts as a brake on the immune system, and is used in combination with durvalumab to treat certain types of liver cancer (hepatocellular carcinoma) and unresectable non-small cell lung cancer. By releasing the immune system's brakes, it helps the body's own defenses attack cancer cells more effectively. Like all checkpoint inhibitors, it can cause serious immune-related side effects affecting any organ in the body.
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Yes, Tremelimumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2108658. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="tremelimumab"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/tremelimumab/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/tremelimumab/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/tremelimumab/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="tremelimumab"></drugfyi-drug>